Standout Papers

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary T... 2011 2026 2016 2021 441
  1. Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer (2011)
    Razelle Kurzrock, Steven I. Sherman et al. Journal of Clinical Oncology

Immediate Impact

1 by Nobel laureates 6 from Science/Nature 79 standout
Sub-graph 1 of 21

Citing Papers

Theranostic Fluorescent Probes
2024 Standout
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
2023 Standout
3 intermediate papers

Works of John Frye being referenced

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
2011 Standout

Author Peers

Author Last Decade Papers Cites
John Frye 284 173 221 226 24 744
Francesca Del Monte 442 159 301 127 26 973
Seiichi Hayato 251 209 119 116 26 833
Bruno Torchio 276 203 193 363 37 955
Yu Jin Kim 293 318 318 82 38 936
Wenhe Zhao 209 101 380 164 44 850
Céline Pallaud 271 123 231 108 32 797
Myriam Decaussin 271 194 495 210 30 920
Peter Gaßmann 374 107 237 81 22 842
Meredith K. Chuk 419 257 169 93 29 835
Sanai Noguchi 201 103 110 147 32 699

All Works

Loading papers...

Rankless by CCL
2026